MEDP vs. RVMD: Medpace vs. Revolution Medicines Stock Comparison

November 11, 2026

How do Medpace (MEDP) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Medpace (MEDP) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while RVMD is classified in Biotechnology.

Company profile comparison for Medpace (MEDP) and Revolution Medicines (RVMD)
Profile Item	MEDP	RVMD
Name	Medpace Holdings, Inc.	Revolution Medicines, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	18.27 billion USD	41.59 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	August 11, 2016	February 13, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

MEDP

RVMD

GSPC

Medpace (MEDP) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Medpace (MEDP) and Revolution Medicines (RVMD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Medpace (MEDP) and Revolution Medicines (RVMD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Medpace (MEDP) and Revolution Medicines (RVMD)
Metric	MEDP	RVMD
Total Return (1Y)	13.29%	224.80%
Total Return (3Y, Annualized)	35.26%	114.71%
Total Return (5Y, Annualized)	24.49%	43.47%

Risk Profile

Drawdown History

MEDP

RVMD

GSPC

Medpace (MEDP) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Medpace (MEDP) and Revolution Medicines (RVMD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Medpace (MEDP) and Revolution Medicines (RVMD)
Metric	MEDP	RVMD
Volatility (1Y, Annualized)	44.16%	68.29%
Beta (5Y)	1.10	1.42
Max Drawdown (5Y)	-42.87%	-55.71%
Avg. Volume (3M)	258.39K	2.06M

Risk-Adjusted Performance

Risk-Return Positioning

MEDP and RVMD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Medpace (MEDP) and Revolution Medicines (RVMD)
Metric	MEDP	RVMD
Sharpe Ratio (1Y)	0.20	3.23
Sortino Ratio (1Y)	0.26	6.92

Profitability

ROE (TTM)

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Medpace (MEDP) reports 117.88%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP: 117.88%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-93.56%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
RVMD: -93.56%
Min: -167.77%

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Medpace (MEDP) at 18.24% converts revenue to bottom-line profit above its industry’s benchmark range, while Revolution Medicines (RVMD) at 0.00% keeps roughly the typical share for its industry.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP: 18.24%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
RVMD: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Medpace (MEDP) reports 23.12%, ranking against industry peers normally.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max: 83.12%
MEDP: 23.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-188.88%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
RVMD: -188.88%
Min: -207.40%

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Medpace (MEDP) and Revolution Medicines (RVMD)
Metric	MEDP	RVMD
ROE (TTM)	117.88%	-93.56%
ROA (TTM)	18.71%	-32.13%
Net Margin (TTM)	18.24%	0.00%
Operating Margin (TTM)	23.12%	-188.88%
Gross Margin (TTM)	72.24%	0.00%

Growth

Revenue Growth

Only one side can be read here: Medpace (MEDP) reports revenue growth of 19.97%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Medpace (MEDP) and Revolution Medicines (RVMD)
Metric	MEDP	RVMD
Revenue Growth (YoY)	19.97%	--
Revenue Growth (3Y CAGR)	20.12%	--
EPS Growth (YoY)	20.98%	--
EPS Growth (3Y CAGR)	28.04%	--

Financial Strength

Current Ratio (MRQ)

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MEDP: 0.83
Min: 0.10

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.36

Max: 25.13
Q3: 12.13
RVMD: 8.36
Median: 5.52
Q1: 2.47
Min: 0.10

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Medpace (MEDP) at 0.29 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max: 1.42
Q3: 0.65
MEDP: 0.29
Median: 0.15
Q1: 0.02
Min: 0.00

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50

Max: 1.42
Q3: 0.65
RVMD: 0.50
Median: 0.15
Q1: 0.02
Min: 0.00

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Medpace (MEDP) and Revolution Medicines (RVMD)
Metric	MEDP	RVMD
Current Ratio (MRQ)	0.83	8.36
Debt / Equity (MRQ)	0.29	0.50
Net Debt / EBITDA	-0.84	--

Dividends

Dividend Yield (TTM)

Neither Medpace (MEDP) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Medpace (MEDP) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Medpace (MEDP) and Revolution Medicines (RVMD)
Metric	MEDP	RVMD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Medpace (MEDP) trades at 36.26 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max: 85.34
Q3: 43.46
MEDP: 36.26
Median: 26.69
Q1: 13.30
Min: 0.07

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
RVMD: --

Medpace (MEDP) vs. Revolution Medicines (RVMD): RVMD does not report P/E ratio, so it has no value marker; MEDP is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Medpace (MEDP) at 6.44 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max: 58.18
Q3: 25.77
Median: 7.30
MEDP: 6.44
Q1: 3.01
Min: 0.01

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

210.51

RVMD: 210.51
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both Medpace (MEDP) at 31.23 and Revolution Medicines (RVMD) at 17.31 look expensive — each P/B ratio sits above its industry’s benchmark range.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP: 31.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.31

RVMD: 17.31
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Medpace (MEDP) vs. Revolution Medicines (RVMD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Medpace (MEDP) and Revolution Medicines (RVMD)
Metric	MEDP	RVMD
P/E Ratio (TTM)	36.26	--
P/S Ratio (TTM)	6.44	210.51
P/B Ratio (MRQ)	31.23	17.31
Free Cash Flow Yield (TTM)	2.72%	-2.13%